Celgene And Three UK Patient Groups Appeal NICE's Rejection Of Vidaza
This article was originally published in The Pink Sheet Daily
Executive Summary
Myelodysplastic patients want access to a Celgene drug rejected as too expensive by UK's health technology assessor.